KEYTRUDA® (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Leerink Partners Reiterates Market Perform on Merck (MRK) Following 3Q EPS Beat
October 28, 2015 9:31 AM EDTLeerink Partners reiterated a Market Perform rating and $67.00 price target on Merck (NYSE: MRK) following the company's 3Q earnings results. MRK reported a $0.04 EPS beat. US sales of Januvia/Janumet increased by 22%, but was benefited by ~$100M due to the timing of consumer buying that is expected to negatively impact future quarters.
Analyst Seamus Fernandez... More
